The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

By Dallob Aimee   Luo Wen-Lin   Luk Julie Mabalot   Ratcliffe Lisa   Johnson-Levonas Amy O.   Schwartz Jules I.   Dishy Victor   Kraft Walter K.   De Hoon Jan N.   Van Hecken Anne   De Lepeleire Inge   Radziszewski Waldemar   Wagner John A.   Lai Eseng  

Platelets, Vol. 22, Iss. 7, 2011-11 ,pp. : 495-503

Informa Healthcare

Access to resources Recommend Favorite

Effect of the Thromboxane Prostaglandin Receptor Antagonist Terutroban on Arterial Thrombogenesis after Repeated Administration in Patients Treated for the Prevention of Ischemic Stroke

By  

Cerebrovascular Diseases, Vol. 28, Iss. 5, 2009-09 ,pp. : 505-513

Karger

Access to resources Recommend Favorite

Oral Antiplatelet Efficacy of the Platelet GPIIb/IIIa Antagonist, DMP754 in Non-Human Primates - Receptor binding affinity & specificity

By Mousa S.A.   Bozarth J.   Youssef A.   Levine B.  

Thrombosis Research, Vol. 89, Iss. 5, 1998-03 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite

Effect of DT-TX 30, a Combined Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, on Retinal Vascularity in Experimental Diabetes Mellitus - A novel device for assessing platelet behavior in blood

By De La Cruz J.P.   Moreno A.   Ruiz-Ruiz M.I.   De La Cuesta F.S.  

Thrombosis Research, Vol. 97, Iss. 3, 2000-02 ,pp. : 125-131

Elsevier

Access to resources Recommend Favorite

The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic GPIIb/IIIa antagonist

By Aoki T.   Cox D.   Senzaki K.   Seki J.   Tanaka A.   Takasugi H.   Motoyama Y.  

Thrombosis Research, Vol. 81, Iss. 4, 1996-02 ,pp. : 439-450

Elsevier

Access to resources Recommend Favorite